Total Payments
$618,967
2024 Payments
$86,930
Companies
18
Transactions
369
Medicare Patients
422
Medicare Billing
$25,756
Payment Breakdown by Category
Other$274,853 (44.4%)
Consulting$224,764 (36.3%)
Travel$71,282 (11.5%)
Research$39,273 (6.3%)
Food & Beverage$8,140 (1.3%)
Education$655.64 (0.1%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $224,764 | 26 | 36.3% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $219,853 | 65 | 35.5% |
| Travel and Lodging | $71,282 | 83 | 11.5% |
| Compensation for serving as faculty or as a speaker for an accredited or certified continuing education program | $55,000 | 1 | 8.9% |
| Unspecified | $39,273 | 37 | 6.3% |
| Food and Beverage | $8,140 | 150 | 1.3% |
| Education | $655.64 | 7 | 0.1% |
Payments by Type
General
$579,694
332 transactions
Research
$39,273
37 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Kaneka Medical America LLC | $176,496 | 4 | $0 (2024) |
| Kaneka Pharma America LLC | $122,557 | 17 | $0 (2021) |
| Amgen Inc. | $107,583 | 115 | $0 (2024) |
| Amarin Pharma Inc. | $58,425 | 83 | $0 (2020) |
| SANOFI-AVENTIS U.S. LLC | $50,853 | 33 | $0 (2019) |
| Regeneron Pharmaceuticals, Inc. | $38,424 | 50 | $0 (2024) |
| Novartis Pharmaceuticals Corporation | $17,338 | 23 | $0 (2024) |
| Grifols, S.A. | $14,384 | 6 | $0 (2022) |
| Esperion Therapeutics, Inc. | $13,561 | 14 | $0 (2024) |
| Regeneron Healthcare Solutions, Inc. | $10,155 | 13 | $0 (2023) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $86,930 | 16 | Kaneka Medical America LLC ($60,425) |
| 2023 | $68,030 | 20 | Kaneka Medical America LLC ($54,138) |
| 2022 | $66,534 | 24 | Kaneka Medical America LLC ($61,932) |
| 2021 | $82,984 | 24 | Kaneka Pharma America LLC ($55,000) |
| 2020 | $76,205 | 28 | Kaneka Pharma America LLC ($59,342) |
| 2019 | $67,420 | 84 | Amarin Pharma Inc. ($24,116) |
| 2018 | $91,599 | 114 | Amgen Inc. ($37,855) |
| 2017 | $79,265 | 59 | Amgen Inc. ($28,409) |
All Payment Transactions
369 individual payment records from CMS Open Payments — Page 1 of 15
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/18/2024 | Novartis Pharmaceuticals Corporation | — | — | Cash or cash equivalent | $5,421.25 | Research |
| Study: Research Publication/ Writing Support | ||||||
| 10/23/2024 | Daxor Corporation | BVA-100 (Device) | Food and Beverage | Cash or cash equivalent | $92.59 | General |
| Category: Diagnostic Test | ||||||
| 09/27/2024 | Amgen Inc. | — | Food and Beverage | In-kind items and services | $24.51 | General |
| 09/17/2024 | Esperion Therapeutics, Inc. | NEXLIZET (Drug), NEXLETOL | Travel and Lodging | In-kind items and services | $9,542.41 | General |
| Category: ANTILIPEMIC AGENTS | ||||||
| 09/01/2024 | Esperion Therapeutics, Inc. | NEXLETOL (Drug) | Food and Beverage | In-kind items and services | $32.74 | General |
| Category: ANTILIPEMIC AGENTS | ||||||
| 08/31/2024 | Esperion Therapeutics, Inc. | NEXLETOL (Drug) | Food and Beverage | In-kind items and services | $51.76 | General |
| Category: ANTILIPEMIC AGENTS | ||||||
| 06/30/2024 | Amgen Inc. | Repatha (Biological) | — | In-kind items and services | $4,342.64 | Research |
| Study: RUTHERFORD HeFH • Category: Cardiology | ||||||
| 06/01/2024 | Esperion Therapeutics, Inc. | NEXLETOL (Drug) | Food and Beverage | In-kind items and services | $138.85 | General |
| Category: ANTILIPEMIC AGENTS | ||||||
| 05/31/2024 | Regeneron Pharmaceuticals, Inc. | EVKEEZA (Biological) | — | In-kind items and services | $327.37 | Research |
| Study: A THREE-PART, SINGLE-ARM, OPEN-LABEL STUDY TO EVALUATE THE EFFICACY, SAFETY, AND PHARMACOKINETICS OF EVINACUMAB IN PEDIATRIC PATIENTS WITH HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA • Category: CARDIOVASCULAR AND METABOLISM | ||||||
| 05/31/2024 | Amgen Inc. | Repatha (Biological) | Food and Beverage | In-kind items and services | $99.23 | General |
| Category: Cardiology | ||||||
| 05/31/2024 | Novartis Pharmaceuticals Corporation | — | Food and Beverage | In-kind items and services | $35.94 | General |
| 05/31/2024 | Amgen Inc. | Repatha (Biological) | Food and Beverage | In-kind items and services | $33.74 | General |
| Category: Cardiology | ||||||
| 05/29/2024 | Kaneka Medical America LLC | — | Food and Beverage | Cash or cash equivalent | $246.67 | General |
| 03/18/2024 | Novartis Pharmaceuticals Corporation | — | — | Cash or cash equivalent | $6,217.00 | Research |
| Study: Review Article | ||||||
| 03/05/2024 | Regeneron Pharmaceuticals, Inc. | EVKEEZA (Biological) | — | In-kind items and services | $145.06 | Research |
| Study: A THREE-PART, SINGLE-ARM, OPEN-LABEL STUDY TO EVALUATE THE EFFICACY, SAFETY, AND PHARMACOKINETICS OF EVINACUMAB IN PEDIATRIC PATIENTS WITH HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA • Category: CARDIOVASCULAR AND METABOLISM | ||||||
| 01/20/2024 | Kaneka Medical America LLC | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $60,178.50 | General |
| 12/15/2023 | Regeneron Pharmaceuticals, Inc. | EVKEEZA (Biological) | Travel and Lodging | In-kind items and services | $5,318.55 | General |
| Category: CARDIOVASCULAR AND METABOLISM | ||||||
| 12/01/2023 | Kaneka Medical America LLC | — | Consulting Fee | Cash or cash equivalent | $54,138.49 | General |
| 11/12/2023 | Novo Nordisk Inc | Ozempic (Drug) | Food and Beverage | In-kind items and services | $20.17 | General |
| Category: Diabetes | ||||||
| 11/11/2023 | Regeneron Pharmaceuticals, Inc. | EVKEEZA (Biological) | — | In-kind items and services | $467.19 | Research |
| Study: A THREE-PART, SINGLE-ARM, OPEN-LABEL STUDY TO EVALUATE THE EFFICACY, SAFETY, AND PHARMACOKINETICS OF EVINACUMAB IN PEDIATRIC PATIENTS WITH HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA • Category: CARDIOVASCULAR AND METABOLISM | ||||||
| 11/08/2023 | Esperion Therapeutics, Inc. | NEXLETOL (Drug) | Food and Beverage | In-kind items and services | $18.49 | General |
| Category: ANTILIPEMIC AGENTS | ||||||
| 10/20/2023 | Regeneron Pharmaceuticals, Inc. | EVKEEZA (Biological) | — | In-kind items and services | $1,504.31 | Research |
| Study: A THREE-PART, SINGLE-ARM, OPEN-LABEL STUDY TO EVALUATE THE EFFICACY, SAFETY, AND PHARMACOKINETICS OF EVINACUMAB IN PEDIATRIC PATIENTS WITH HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA • Category: CARDIOVASCULAR AND METABOLISM | ||||||
| 08/10/2023 | Regeneron Pharmaceuticals, Inc. | PRALUENT (Biological) | Travel and Lodging | In-kind items and services | $160.26 | General |
| Category: CARDIOVASCULAR AND METABOLISM | ||||||
| 06/09/2023 | Regeneron Healthcare Solutions, Inc. | EVKEEZA (Biological) | Consulting Fee | Cash or cash equivalent | $1,586.00 | General |
| Category: CARDIOVASCULAR AND METABOLISM | ||||||
| 06/01/2023 | Regeneron Pharmaceuticals, Inc. | EVKEEZA (Biological) | — | In-kind items and services | $555.75 | Research |
| Study: AN OPEN-LABEL STUDY TO EVALUATE THE LONG-TERM SAFETY AND EFFICACY OF EVINACUMAB IN PATIENTS WITH HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA • Category: CARDIOVASCULAR AND METABOLISM | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| MEASuRE | Aegerion Pharmaceuticals, Inc. | $8,095 | 2 |
| Review Article | Novartis Pharmaceuticals Corporation | $6,217 | 1 |
| Research Publication/ Writing Support | Novartis Pharmaceuticals Corporation | $5,421 | 1 |
| RUTHERFORD HeFH | Amgen Inc. | $4,343 | 1 |
| PRALUENT CLINICAL DEVELOPMENT PROGRAM | Regeneron Pharmaceuticals, Inc. | $4,010 | 5 |
| A THREE-PART, SINGLE-ARM, OPEN-LABEL STUDY TO EVALUATE THE EFFICACY, SAFETY, AND PHARMACOKINETICS OF EVINACUMAB IN PEDIATRIC PATIENTS WITH HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA | Regeneron Pharmaceuticals, Inc. | $3,054 | 7 |
| A PHASE 2, RANDOMIZED, PLACEBO-CONTROLLED STUDY OF SAFETY AND EFFICACY, FOLLOWING REPEAT-DOSE ADMINISTRATION OF EVINACUMAB (ANTI-ANGPTL3) IN PATIENTS WITH SEVERE HYPERTRIGLYCERIDEMIA (SHTG) AT RISK FOR ACUTE PANCREATITIS | Regeneron Pharmaceuticals, Inc. | $2,493 | 2 |
| AN OPEN-LABEL STUDY TO EVALUATE THE LONG-TERM SAFETY AND EFFICACY OF EVINACUMAB IN PATIENTS WITH HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA | Regeneron Pharmaceuticals, Inc. | $2,012 | 5 |
| A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ALIROCUMAB IN PATIENTS WITH HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA UNDERGOING LIPID APHERESIS THERAPY | Regeneron Pharmaceuticals, Inc. | $1,126 | 6 |
| Evinacumb Clinical Development Program | Regeneron Pharmaceuticals, Inc. | $1,066 | 2 |
| A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF AN EVERY FOUR WEEKS TREATMENT REGIMEN OF ALIROCUMAB IN PATIENTS WITH PRIMARY HYPERCHOLESTEROLEMIA | Regeneron Pharmaceuticals, Inc. | $849.71 | 3 |
| EVINACUMB CLINICAL DEVELOPMENT PROGRAM | Regeneron Pharmaceuticals, Inc. | $586.40 | 2 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 2 | 60 | 61 | $9,233 | $3,912 |
| 2022 | 4 | 105 | 105 | $11,558 | $5,874 |
| 2021 | 2 | 128 | 133 | $15,772 | $8,565 |
| 2020 | 3 | 129 | 135 | $22,864 | $7,406 |
Total Patients
422
Total Services
434
Medicare Billing
$25,756
Procedure Codes
11
All Medicare Procedures & Services
11 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99443 | Telephone medical discussion with physician, 21-30 minutes | Facility | 2023 | 47 | 47 | $7,593 | $3,259 | 42.9% |
| 99442 | Telephone medical discussion with physician, 11-20 minutes | Facility | 2023 | 13 | 14 | $1,640 | $653.38 | 39.8% |
| 99443 | Telephone medical discussion with physician, 21-30 minutes | Facility | 2022 | 58 | 58 | $5,510 | $3,384 | 61.4% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2022 | 21 | 21 | $2,926 | $1,019 | 34.8% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2022 | 14 | 14 | $2,354 | $859.88 | 36.5% |
| 99442 | Telephone medical discussion with physician, 11-20 minutes | Facility | 2022 | 12 | 12 | $768.00 | $610.45 | 79.5% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Facility | 2021 | 60 | 62 | $9,614 | $4,330 | 45.0% |
| 99443 | Physician telephone patient service, 21-30 minutes of medical discussion | Facility | 2021 | 68 | 71 | $6,158 | $4,235 | 68.8% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Facility | 2020 | 71 | 77 | $12,624 | $2,978 | 23.6% |
| 99205 | New patient office or other outpatient visit, typically 60 minutes | Facility | 2020 | 30 | 30 | $8,084 | $2,932 | 36.3% |
| 99443 | Physician telephone patient service, 21-30 minutes of medical discussion | Facility | 2020 | 28 | 28 | $2,156 | $1,496 | 69.4% |
About Dr. Patrick Moriarty, M.D
Dr. Patrick Moriarty, M.D is a Internal Medicine healthcare provider based in Kansas City, Kansas. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 09/05/2006. The National Provider Identifier (NPI) number assigned to this provider is 1356443675.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Patrick Moriarty, M.D has received a total of $618,967 in payments from pharmaceutical and medical device companies, with $86,930 received in 2024. These payments were reported across 369 transactions from 18 companies. The most common payment nature is "Consulting Fee" ($224,764).
As a Medicare-enrolled provider, Moriarty has provided services to 422 Medicare beneficiaries, totaling 434 services with total Medicare billing of $25,756. Data is available for 4 years (2020–2023), covering 11 distinct procedure/service records.
Ad
Practice Information
- Specialty Internal Medicine
- Other Specialties Clinical Pharmacology
- Location Kansas City, KS
- Active Since 09/05/2006
- Last Updated 05/29/2014
- Taxonomy Code 207R00000X
- Entity Type Individual
- NPI Number 1356443675
Products in Payments
- Repatha (Biological) $78,137
- Liposober (Device) $61,932
- LIPOSORBER (Device) $59,342
- Vascepa (Drug) $58,425
- PRALUENT (Drug) $47,873
- PRALUENT ALIROCUMAB INJECTION (Biological) $23,542
- EVKEEZA (Biological) $18,722
- NEXLIZET (Drug) $13,276
- MYALEPT (Drug) $8,095
- PRALUENT (Biological) $4,753
- DISEASE STATE (Drug) $3,075
- PELACARSEN (Drug) $1,908
- NEXLETOL (Drug) $285.83
- ENTRESTO (Drug) $193.16
- Livalo (Drug) $145.26
- BVA-100 (Device) $92.59
- LEQVIO (Drug) $48.62
- TEGSEDI (Drug) $43.10
- Corlanor (Drug) $36.34
- Ozempic (Drug) $20.17
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Internal Medicine Doctors in Kansas City
James O'keefe, Md, MD
Internal Medicine — Payments: $834,178
Internal Medicine $834,178
Shadi Hamdeh, Md, MD
Internal Medicine — Payments: $623,244
Internal Medicine $623,244
Gerald Mancuso, M.d, M.D
Internal Medicine — Payments: $615,894
Internal Medicine $615,894
Dr. Ryan Taylor, M.d, M.D
Internal Medicine — Payments: $512,094
Internal Medicine $512,094
Sanjaya Gupta, Md, MD
Internal Medicine — Payments: $325,155
Internal Medicine $325,155
Dr. Craig Dietz, D.o, D.O
Internal Medicine — Payments: $285,115
Internal Medicine $285,115